Skip to main content

Advertisement

Log in

Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia

  • Original Paper
  • Published:
Analytical and Bioanalytical Chemistry Aims and scope Submit manuscript

Abstract

Arsenic trioxide (As2O3) has been widely accepted as the second-best choice for the treatment of relapsed and refractory acute promyelocytic leukemia (APL) patients. However, a few studies have been conducted on a detailed speciation of As2O3 metabolites in blood samples of patients. To clarify the speciation of arsenic, the blood samples were collected at various time points from a patient with APL after remission induction therapy and during consolidation therapy. The total amounts of arsenic in blood cells and plasma, and the plasma concentrations of inorganic arsenic and methylated metabolites were determined by inductively coupled plasma mass spectrometry (ICP-MS) and high-performance liquid chromatography/ICP-MS, respectively. The total amounts of arsenic in the blood cells were 4–10 times higher than those in plasma. Among all arsenic metabolites, the pentavalent arsenate (AsV) in plasma was more readily eliminated. During the drug-withdrawal period, the initial plasma concentrations of trivalent arsenic (AsIII) declined more rapidly than those of methylarsonic acid and dimethlyarsinic acid, which are known as the major methylated metabolites of AsIII. On the other hand, during the consecutive administration in the consolidation therapy period, the plasma concentrations of total arsenic and arsenic metabolites increased with time. In conclusion, these results may support the idea that methylated metabolites of As2O3 contribute to the efficacy of arsenic in APL patients. These results also suggest that detailed studies on the pharmacokinetics as well as the pharmacodynamics of As2O3 in the blood cells from APL patients should be carried out to provide an effective treatment protocol.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Goddard AD, Borrow J, Freemont PS, Solomon E (1991) Science 254:1371–1374

    Article  CAS  Google Scholar 

  2. Tong JH, Dong S, Geng JP, Huang W, Wang ZY, Sun GL, Chen SJ, Chen Z, Larsen CJ, Berger R (1992) Oncogene 7:311–316

    CAS  Google Scholar 

  3. de Thé H, Chomienne C, Lanotte M, Degos L, Dejean A (1990) Nature 347:558–561

    Article  Google Scholar 

  4. Melnick A, Licht JD (1999) Blood 93:3167–3215

    CAS  Google Scholar 

  5. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH (1999) Blood 93:4131–4143

    CAS  Google Scholar 

  6. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY (1997) Blood 89:3354–3360

    CAS  Google Scholar 

  7. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr (1998) N Engl J Med 339:1341–1348

    Article  CAS  Google Scholar 

  8. Cohen MH, Hirschfeld S, Flamm Honig S, Ibrahim A, Johnson JR, O’Leary JJ, White RM, Williams GA, Pazdur R (2001) Oncologist 6:4–11

    Article  CAS  Google Scholar 

  9. Ohnishi K, Yoshida H, Shigeno K, Nakamura S, Fujisawa S, Naito K, Shinjo K, Fujita Y, Matsui H, Sahara N, Takeshita A, Satoh H, Terada H, Ohno R (2002) Leukemia 16:617–622

    Article  CAS  Google Scholar 

  10. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr (2001) J Clin Oncol 19:3852–3860

    CAS  Google Scholar 

  11. Aposhian HV (1997) Annu Rev Pharmacol Toxicol 37:397–419

    Article  CAS  Google Scholar 

  12. Kitchin KT (2001) Toxicol Appl Pharmacol 172:249–261

    Article  CAS  Google Scholar 

  13. Del Razo LM, Styblo M, Cullen WR, Thomas DJ (2001) Toxicol Appl Pharmacol 174:282–293

    Article  CAS  Google Scholar 

  14. Aposhian HV, Gurzau ES, Le XC, Gurzau A, Healy SM, Lu X, Ma M, Yip L, Zakharyan RA, Maiorino RM, Dart RC, Tircus MG, Gonzalez-Ramirez D, Morgan DL, Avram D, Aposhian MM (2000) Chem Res Toxicol 13:693–697

    Article  CAS  Google Scholar 

  15. Wang Z, Zhou J, Lu X, Gong Z, Le XC (2004) Chem Res Toxicol 17:95–103

    Article  CAS  Google Scholar 

  16. Styblo M, Del Razo LM, Vega L, Germolec DR, LeCluyse EL, Hamilton GA, Reed W, Wang C, Cullen WR, Thomas DJ (2000) Arch Toxicol 74:289–299

    Article  CAS  Google Scholar 

  17. Chen GQ, Zhou L, Styblo M, Walton F, Jing Y, Weinberg R, Chen Z, Waxman S (2003) Cancer Res 63:1853–1859

    CAS  Google Scholar 

  18. Aposhian HV, Zakharyan RA, Avram MD, Sampayo-Reyes A, Wollenberg ML (2004) Toxicol Appl Pharmacol 198:327–335

    Article  Google Scholar 

  19. Fukai Y, Hirata M, Ueno M, Ichikawa N, Kobayashi H, Saitoh H, Sakurai T, Kinoshita K, Kaise T, Ohta S (2006) Biol Pharm Bull 29:1022–1027

    Article  CAS  Google Scholar 

  20. Fujisawa S, Ohno R, Shigeno K, Sahara N, Nakamura S, Naito K, Kobayashi M, Shinjo K, Takeshita A, Suzuki Y, Hashimoto H, Kinoshita K, Shimoya M, Kaise T, Ohnishi K (2007) Cancer Chemother Pharmacol 59:485–493

    Article  CAS  Google Scholar 

  21. Shibata Y, Yoshinaga J, Morita M (1994) Appl Organomet Chem 8:249–251

    Article  CAS  Google Scholar 

  22. Douer D, Tallman MS (2005) J Clin Oncol 23:2396–2410

    Article  CAS  Google Scholar 

  23. Raffoux E, Rousselot P, Poupon J, Daniel MT, Cassinat B, Delarue R, Taksin AL, Réa D, Buzyn A, Tibi A, Lebbé G, Cimerman P, Chomienne C, Fermand JP, de Thé H, Degos L, Hermine O, Dombret H (2003) J Clin Oncol 21:2326–2334

    Article  CAS  Google Scholar 

  24. Rousselot P, Larghero J, Arnulf B, Poupon J, Royer B, Tibi A, Madelaine-Chambrin I, Cimerman P, Chevret S, Hermine O, Dombret H, Claude Brouet J, Paul Fermand J (2004) Leukemia 18:1518–1521

    Article  CAS  Google Scholar 

  25. Westervelt P, Brown RA, Adkins DR, Khoury H, Curtin P, Hurd D, Luger SM, Ma MK, Ley TJ, DiPersio JF (2001) Blood 98:266–271

    Article  CAS  Google Scholar 

  26. Lu M, Wang H, Li XF, Lu X, Cullen WR, Arnold LL, Cohen SM, Le XC (2004) Chem Res Toxicol 17:1733–1742

    Article  CAS  Google Scholar 

  27. Benramdane L, Accominotti M, Fanton L, Malicier D, Vallon JJ (1999) Clin Chem 45:301–306

    CAS  Google Scholar 

  28. Slejkovec Z, Falnoga I, Goessler W, van Elteren JT, Raml R, Podgornik H, Cernelc P (2008) Anal Chim Acta 607:83–91

    Article  CAS  Google Scholar 

  29. Naranmandura H, Suzuki KT (2008) Toxicol Appl Pharmacol 227:390–399

    Article  CAS  Google Scholar 

Download references

Acknowledgements

This work was supported in part by grants from the Ministry of Education, Culture, Sports, Science and Technology and by the Promotion and Mutual Aid Corporation for Private Schools of Japan. We acknowledge Nippon Shinyaku Co. Ltd. for generous supply of Trisenox®.

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to Bo Yuan or Toshikazu Kaise.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Table S1

Analytical Conditions of ICP-MS (PDF 14.05 KB)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yoshino, Y., Yuan, B., Miyashita, Si. et al. Speciation of arsenic trioxide metabolites in blood cells and plasma of a patient with acute promyelocytic leukemia. Anal Bioanal Chem 393, 689–697 (2009). https://doi.org/10.1007/s00216-008-2487-9

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00216-008-2487-9

Keywords

Navigation